CLDI - Calidi Biotherapeutics Inc

0.22
-0.011   -5.136%

Share volume: 1,914,128
Last Updated: 04-23-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$0.23
-0.01
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 35%
Dept financing 35%
Liquidity 42%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-12.07%
1 Month
-22.67%
3 Months
-78.43%
6 Months
-85.71%
1 Year
-55.76%
2 Year
39.33%
Key data
Stock price
$0.22
P/E Ratio 
N/A
DAY RANGE
$0.21 - $0.23
EPS 
-$4.73
52 WEEK RANGE
$0.20 - $7.25
52 WEEK CHANGE
-$54.45
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
10.896 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
0.94
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,992,409
AVERAGE 30 VOLUME 
$1,918,818
Company detail
CEO: Allan J. Camaisa
Region: US
Website: www.calidibio.com
Employees: 38
IPO year: 2021
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. The company was founded in 2014 and is based in San Diego, California.

Recent news